source stringlengths 2 222 | date stringlengths 19 19 | url stringlengths 22 853 ⌀ | text stringlengths 0 10k ⌀ | title stringlengths 0 701 | context_id stringlengths 1 9 | document_id stringclasses 2
values | document_type stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Seeking Alpha | 2022-09-19 11:32:59 | https://seekingalpha.com/article/4541828-abbvie-valuation-attractive-due-to-humira-headwinds | AbbVie is a global biopharmaceutical company with a vast portfolio of drugs and therapies. Its blockbuster drug, Humira, is set to lose exclusivity in 2023. | AbbVie: Valuation Attractive Due To Humira Headwinds | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2022-09-17 13:13:30 | https://www.forbes.com/sites/brianbushard/2022/09/17/calif-pharmaceutical-companies-abbvie-and-bristol-myers-lay-off-360-here-are-the-major-us-layoffs-this-summer/ | Forbes is tracking the biggest layoffs in the U.S. this summer as companies react to fears of a looming recession. | Calif. Pharmaceutical Companies AbbVie And Bristol Myers Lay Off 360—Here Are The Major U.S. Layoffs This Summer | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2022-09-15 20:41:20 | https://www.reuters.com/business/healthcare-pharmaceuticals/consumer-group-says-drugmakers-abuse-us-patent-system-keep-prices-high-2022-09-16/ | Makers of the top selling drugs in the United States are costing patients billions of dollars and worsening a drug pricing crisis by abusing the U.S. patent system to stifle competition and inflate prices, a consumer group said on Thursday, | Consumer group says drugmakers abuse U.S. patent system to keep prices high | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-09-15 18:42:19 | https://seekingalpha.com/article/4541330-outlooks-for-abbvie-continue-to-look-favorable | AbbVie has delivered strong earnings over recent quarters. The total return on ABBV over the past year is 36.6%. | Outlook For AbbVie Continues To Look Favorable | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-09-15 15:00:16 | https://investorplace.com/2022/09/7-top-rated-biotech-stocks-to-buy-for-q4/ | A new White House program will likely boost the entire biotech industry. And it makes these seven names some outstanding biotech stocks to buy for the fourth quarter. | 7 Top-Rated Biotech Stocks to Buy for Q4 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2022-09-15 02:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-data-from-growing-neuroscience-and-movement-disorders-portfolio-at-2022-mds-international-congress-301624493.html | --Results will be presented from the Phase 3 M15-736 trial, a randomized, double-blind, double-dummy, active-controlled study, evaluating the continuous subcutaneous infusion of ABBV-951 (foslevodopa/foscarbidopa) in people with advanced Parkinson's disease --Data will also be presented on real-world efficacy of BOTOX®... | AbbVie to Present Data from Growing Neuroscience and Movement Disorders Portfolio at 2022 MDS International Congress | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-09-14 12:26:06 | https://seekingalpha.com/article/4540985-abbvie-inc-s-abbv-management-presents-morgan-stanley-20th-annual-global-healthcare-conference | AbbVie Inc. (NYSE:ABBV ) Morgan Stanley 20th Annual Global Healthcare Conference September 13, 2022 10:35 AM ET Company Participants Rob Michael - Vice Chairman and President Jeff Stewart - Executive Vice President and Chief Commercial Officer Neil Gallagher - Vice President, Development and Chief Medical Officer Confe... | AbbVie Inc.'s (ABBV) Management Presents at Morgan Stanley 20th Annual Global Healthcare Conference (Transcript) | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-13 05:25:00 | https://www.fool.com/investing/2022/09/13/3-unstoppable-dividend-stocks-to-buy-in-september/ | These stocks offer more than just dividends. | 3 Unstoppable Dividend Stocks to Buy in September | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-09-12 16:38:23 | https://www.youtube.com/watch?v=WKjJk1ztFQo | Mohit Bansal, Wells Fargo, joins 'Closing Bell' to discuss Bristol-Myers shares rising on the FDA approval of its latest drug. | Wells Fargo's Mohit Bansal: Abbvie has better long-term opportunity than Bristol-Myers | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-12 06:27:00 | https://www.fool.com/investing/2022/09/12/2-dividend-aristocrats-that-could-help-income-inve/ | This pair of Midwestern companies have outperformed in recent years, and their futures look brighter than ever. | 2 Dividend Aristocrats to Buy for Passive Income That Could Outperform the Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-09-11 15:18:26 | https://seekingalpha.com/article/4540250-4-s-and-p500-dividend-aristocrat-1-to-watch | "Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 65 Aristocrats screened as of September 8, 2022 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 16.54%-36.34% topped by VFC & SWK. | 4 S&P 500 Dividend Aristocrat Dogs To Buy, 1 To Watch | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-09-11 12:10:04 | https://stockmarket.com/featured/best-stocks-to-buy-now-4-biotech-stocks-in-focus-2022-09-11 | Is now a good time to add these biotech stocks to your watchlist? | Best Stocks To Buy Now? 4 Biotech Stocks In Focus | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-09-09 10:32:18 | https://www.zacks.com/stock/news/1978625/is-most-watched-stock-abbvie-inc-abbv-worth-betting-on-now | Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. | Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-09-08 12:14:39 | https://investorplace.com/2022/09/7-sp-500-stocks-to-buy-with-superior-fundamentals/ | Starting the session following Labor Day weekend in the red, it's clear that even so-called S&P 500 stocks to buy are feeling the heat. Toward the end of August, Federal Reserve chair Jerome Powell presented a less-than-encouraging picture for future monetary policy. | 7 S&P 500 Stocks to Buy With Superior Fundamentals | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2022-09-08 04:00:00 | https://www.prnewswire.com/news-releases/abbvie-to-present-data-from-its-robust-migraine-portfolio-at-the-migraine-trust-international-symposium-2022-301619909.html | --Results from the PROGRESS Phase 3 trial on atogepant for the preventive treatment of chronic migraine will be showcased as an oral presentation --Breadth of research underscores AbbVie's leadership and commitment to people living with migraine NORTH CHICAGO, Ill. , Sept. 8, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) to... | AbbVie to Present Data From its Robust Migraine Portfolio at the Migraine Trust International Symposium 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-09-07 14:03:50 | https://www.youtube.com/watch?v=Ucsz8Fb1uOg | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: Abbvie, Tesla, Alaska Air & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Invezz | 2022-09-05 15:54:20 | https://invezz.com/news/2022/09/05/two-dividend-stocks-worth-owning-right-now/ | Historically, September tends to be the worst month for the benchmark S&P 500 index. Still, the following two mega-cap names, according to experts, are worth owning here. | Two dividend stocks worth owning for a tough September | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-05 05:52:00 | https://www.fool.com/investing/2022/09/05/dividend-aristocrats-buy-beat-market-over-next-10/ | These companies don't just have impressive dividend track records. | 3 Dividend Aristocrats to Buy That Could Beat the Market Over the Next 10 Years | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-04 06:30:00 | https://www.fool.com/investing/2022/09/04/2-top-biotech-stocks-to-buy-right-now/ | They have what it takes to generate major revenue over the years to come. | 2 Top Biotech Stocks to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-03 11:22:18 | https://www.fool.com/investing/2022/09/03/10-best-dividend-stocks-to-buy-now-in-september/ | These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio. | 10 Best Dividend Stocks to Buy Now in September | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-09-03 06:08:00 | https://www.fool.com/investing/2022/09/03/3-great-dividend-stocks-to-buy-in-september/ | One word describes these three stocks and their dividends -- solid. | 3 Great Dividend Stocks to Buy in September | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-09-02 19:19:06 | https://www.youtube.com/watch?v=eddF1ysiocs | Kevin Simpson of Capital Wealth Planning and Andrew Graham of Jackson Square Capital join Becky Quick and the 'CNBC Special: Back to Business' to reveal their favorite stock picks. | Stock picks for a tough month | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-09-01 13:58:13 | https://www.youtube.com/watch?v=7-FaNhQGXW8 | The "Halftime Report" traders give their top picks to watch for the second half. | Final Trades: CME, Abbvie & more | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Finbold | 2022-09-01 08:53:30 | https://finbold.com/top-2-dividend-shares-to-navigate-stock-market-in-h2-2022/?SNAPI | Yield is not the be-all and end-all when picking out the best dividend stocks, especially in a volatile market like | Top 2 dividend shares to navigate stock market in H2, 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2022-08-31 15:26:38 | https://www.investors.com/news/technology/biotech-stocks-the-top-5-to-watch-amid-a-blazing-hot-run/ | The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders. | Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-08-29 10:32:23 | https://www.zacks.com/stock/news/1973311/abbvie-inc-abbv-is-attracting-investor-attention-here-is-what-you-should-know | Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-08-26 01:05:07 | https://www.marketbeat.com/originals/should-abbvie-inc-have-a-place-in-your-dividend-portfolio/?SNAPI | Does AbbVie Inc. fit well into your portfolio? We'll take a look at several factors before you decide whether investing in shares makes sense for your needs. | Should AbbVie Inc. Have a Place in Your Dividend Portfolio? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-08-25 14:18:09 | https://www.zacks.com/stock/news/1972599/abbvie-abbv-j-j-s-imbruvica-gets-fda-nod-for-cgvhd-in-kids | AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patients | AbbVie (ABBV), J&J's Imbruvica Gets FDA Nod for cGVHD in Kids | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2022-08-25 11:41:15 | https://www.investors.com/news/technology/abbvie-stock-buy-now/ | Is AbbVie stock a buy today with its biggest medicine, Humira, soon to face biosimilar rivals in the U.S.? The post Is AbbVie Stock A Buy Or A Sell With Humira Rivals Looming? | Is AbbVie Stock A Buy Or A Sell With Humira Rivals Looming? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-08-24 11:48:31 | https://stockmarket.com/featured/top-stocks-to-buy-now-3-dividend-paying-stocks-to-watch-today-2022-08-24 | Check out these three top dividend paying stocks in the stock market this week. | Top Stocks To Buy Now? 3 Dividend Paying Stocks To Watch Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-08-24 06:01:00 | https://www.fool.com/investing/2022/08/24/want-passive-income-invest-in-3-dividend-kings/ | These companies have raised their payouts to shareholders throughout multiple recessions, military conflicts, and a global pandemic. | Want Passive Income? Invest In These 3 Dividend Kings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-08-23 15:51:35 | https://www.youtube.com/watch?v=xahsG5_hf18 | Quint Tatro, founder and president of Joule Financial joins 'Power Lunch' to discuss stocks with low beta, stable yields and positive returns so far this year. | Joule Financial founder on low-volatility stocks: Kraft, Kinder Morgan, and Abbvie | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2022-08-23 12:15:00 | https://www.marketwatch.com/story/these-3-safe-stocks-yield-more-that-10-year-treasurys-11661271337 | After the volatility of early 2022 and the aggressive rate tightening by the Fed, there's a return of chatter about the “Great Rotation” – that is, a broad move among investors to reduce exposure to growth-oriented stocks and increase their positions in value stocks as well as bonds. | These 3 safe stocks yield more that 10-year Treasurys | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-08-23 07:45:10 | https://investorplace.com/2022/08/7-top-rated-large-cap-stocks-to-buy-and-hold-2/ | Top-rated large-cap stocks can offer a bit of security in volatile times. After the relief rally earlier this month, stocks may be in for another bout of weakness. | 7 Top-Rated Large-Cap Stocks to Buy and Hold | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-08-22 12:00:46 | https://investorplace.com/best-bargain-stocks/ | Given the unique circumstances associated with the Covid-19 pandemic, investors may want to take a step back from the crowd and consider the best bargain stocks to buy now. To be sure, several equity-based opportunities printed much red ink this year, presenting cheap prospects to consider. | The 7 Best Bargain Stocks to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-08-22 10:07:00 | https://www.fool.com/investing/2022/08/22/2-top-healthcare-stocks-defying-the-bear-market/ | Not all companies are struggling right now. | 2 Top Healthcare Stocks Defying the Bear Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-08-21 09:30:00 | https://www.fool.com/investing/2022/08/21/which-growth-stock-is-better-buy-right-now-abbvie-/ | These beaten-down stocks share a favorable outlook for their aesthetic segments. | Which Growth Stock Is a Better Buy Right Now -- AbbVie or InMode? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-08-19 17:48:01 | https://seekingalpha.com/article/4535854-abbvie-vs-pfizer-impact-of-the-inflation-reduction-act-on-their-future | Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. | AbbVie Vs. Pfizer: Impact Of The Inflation Reduction Act On Their Future | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-08-19 13:40:10 | https://www.youtube.com/watch?v=rgbc_oOJMPQ | Favorite dividend stock picks right now. With CNBC's Frank Holland the the 'Halftime Report' investment committee, Rob Sechan, Kevin O'Leary, Richard Saperstein and Shannon Saccocia | The 'Halftime Report' investment committee offers its dividend picks | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-08-18 09:47:12 | https://www.zacks.com/stock/news/1969617/abbvie-abbv-outperforms-industry-this-year-so-far-here-s-why | AbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential. | AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-08-18 09:10:00 | https://www.fool.com/investing/2022/08/18/3-top-dividend-kings-to-buy-for-the-long-haul/ | You'll need to hold these stocks for many years to get the full benefit of their consistent dividend growth. | 3 Top Dividend Kings to Buy for the Long Haul | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-08-16 10:32:19 | https://www.zacks.com/stock/news/1968498/abbvie-inc-abbv-is-a-trending-stock-facts-to-know-before-betting-on-it | Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. | AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-08-15 15:52:08 | https://seekingalpha.com/article/4534532-abbvie-outstanding-portfolio-performance-continues | Skyrizi and Rinvoq are performing exceptionally (expected to deliver $7.5 B sales this year). Neuroscience, aesthetics, and oncology are showing strong growth as well. | AbbVie: Outstanding Portfolio Performance Continues | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-08-15 14:40:53 | https://seekingalpha.com/article/4534514-abbvie-still-solid-buy-after-modelling-sales-2030 | AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. The Immunology division looks strong, even factoring in the patent cliff faced by $20 billion-selling Humira. | AbbVie: Still A Solid Buy After Modeling Sales To 2030 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
CNBC Television | 2022-08-13 00:01:46 | https://www.youtube.com/watch?v=mjpXOKi2800 | Gina Sanchez, Chantico Global CEO, joins 'The Exchange' to discuss her three investment picks for being defensive in the market. | Chantico Global CEO Gina Sanchez offers 3 buys and a bail: V, ABBV, DIS & NFLX | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Yahoo Finance | 2022-08-11 13:45:08 | https://www.youtube.com/watch?v=PvsOOk2au-0 | Yahoo Finance's Anjalee Khemlani breaks down the impacts the Inflation Reduction Act could have on Medicare enrollees should Congress pass it. | How the Inflation Reduction Act will affect Medicare | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2022-08-10 10:05:00 | https://www.marketwatch.com/story/10-defensive-stocks-that-can-also-provide-you-with-growth-and-dividends-over-the-long-term-11660140315 | The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet. | 10 defensive stocks that can also provide you with growth and dividends over the long term | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-08-09 10:23:25 | https://investorplace.com/2022/08/blue-chip-stocks-that-will-survive-2022/ | Buying high-quality blue-chip stocks in a bear market could be a solid path to generating lucrative long-term returns. Blue-chip stocks are typically large-cap businesses in the mature stage of their business cycle. | 7 Blue-Chip Stocks That Will Survive 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-08-08 22:15:57 | https://seekingalpha.com/article/4531728-buy-4-sp-500-august-dog-days-dividend-aristocrats | "Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 65 Aristocrats screened as of August 4, 2022 represented all eleven Morningstar Sectors. Broker estimated top-ten net gains ranged 14.54%-40.69% topped by XOM & SWK. | Buy 4 S&P 500 August Dog Days Dividend Aristocrats | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-08-08 15:55:53 | https://investorplace.com/undervalued-value-stocks/ | Value stocks are always a sensible class of equities to consider as an investment. It's all about finding stocks that are believed to be trading below where they should be based on fundamental metrics. | The 7 Most Undervalued Value Stocks to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-08-08 11:11:53 | https://www.marketbeat.com/originals/two-appealing-biotech-stocks-for-two-distinct-investors/?SNAPI | Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles | Two Appealing Biotech Stocks for Two Distinct investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-08-07 09:00:00 | https://www.fool.com/investing/2022/08/07/3-unstoppable-stocks-that-dont-care-about-the-bear/ | When the market is falling, this trio keeps rising. | 3 Unstoppable Stocks That Don't Care About the Bear Market | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-08-06 06:08:00 | https://www.fool.com/investing/2022/08/06/3-unstoppable-dividend-stocks-to-buy-in-august/ | Income investors have a lot to like about these stocks. | 3 Unstoppable Dividend Stocks to Buy in August | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-08-05 10:32:21 | https://www.zacks.com/stock/news/1964647/investors-heavily-search-abbvie-inc-abbv-here-is-what-you-need-to-know | AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-08-05 10:00:00 | https://www.fool.com/investing/2022/08/05/3-reasons-why-abbvie-stock-could-be-approaching-a/ | It won't be able to rely on Humira for growth for much longer. | 3 Reasons Why AbbVie Stock Could Be Approaching a Make or Break Moment | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-08-04 08:00:00 | https://seekingalpha.com/article/4529126-johnson-and-johnson-abbvie-great-dividend-aristocrats-whats-coming-next | The 2022 bear market might not be over, with some blue-chip economists predicting a further 18% to 43% decline before we bottom. JNJ and ABBV are two defensive healthcare dividend kings, which are up in 2022, helping investors sleep well at night in these turbulent times. | Johnson & Johnson And AbbVie: 2 Great Dividend Aristocrats For What's Coming Next | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-08-04 06:06:01 | https://www.marketbeat.com/originals/3-pharma-stocks-post-earnings-price-moves/?SNAPI | The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market. | 3 Pharma Stocks' Post-Earnings Price Moves | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Forbes | 2022-08-02 08:01:21 | https://www.forbes.com/sites/dividendchannel/2022/08/02/why-abbvie-is-a-top-25-dividend-giant/ | AbbVie has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $30.38B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 4.02% yield | Why AbbVie Is A Top 25 Dividend Giant | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-08-01 08:38:00 | https://seekingalpha.com/article/4528206-merck-abbvie-q2-pipeline-dividends-focus | Both Merck and AbbVie reported their Q2 earnings last week, and this article provides a review of their earnings. We like both given their strong pipeline and safe dividends. | Merck And AbbVie Q2: Pipeline And Dividends In Focus | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-31 05:57:00 | https://www.fool.com/investing/2022/07/31/3-dividend-aristocrats-to-buy-in-august/ | These stocks have reliable dividends and strong underlying businesses. | 3 Dividend Aristocrats to Buy in August | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-30 11:00:00 | https://www.fool.com/investing/2022/07/30/earn-300-in-quarterly-retirement-dividends-with-3/ | With the market down close to 20% this year, passive income has become more important. | Earn $300 in Quarterly Retirement Dividends With 3 Easy Steps | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-30 06:08:00 | https://www.fool.com/investing/2022/07/30/3-stocks-we-think-could-beat-the-market-in-the-sec/ | These stocks share several things in common. | 3 Stocks We Think Could Beat the Market in the Second Half of 2022 | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-29 18:21:49 | https://www.fool.com/investing/2022/07/29/why-abbvie-stock-is-tanking-today/ | The drugmaker's Q2 results aren't sitting well with shareholders today. | Why AbbVie Stock Is Tanking Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-29 17:07:09 | https://www.zacks.com/stock/news/1960938/abbvie-s-abbv-q2-earnings-beat-estimates-revenues-lag | AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales. | AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-07-29 15:36:11 | https://seekingalpha.com/article/4527609-abbvie-inc-abbv-ceo-rick-gonzalez-on-q2-2022-results-earnings-call-transcript | AbbVie Inc. (NYSE:ABBV ) Q2 2022 Results Conference Call July 29, 2022 9:00 AM ET Company Participants Liz Shea - Head, IR Rick Gonzalez - Chairman and CEO Rob Michael - Vice Chairman and President Jeff Stewart - EVP and Chief Commercial Officer Tom Hudson - SVP R&D, and Chief Scientific Officer Carrie Strom - SVP, and... | AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2022 Results - Earnings Call Transcript | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-07-29 11:39:24 | https://investorplace.com/2022/07/abbv-stock-slips-as-abbvie-faces-opioid-lawsuits/ | AbbVie (NYSE: ABBV ) recently published the company's second-quarter 2022 financial data. The results weren't very different from what Wall Street's analysts had expected. | ABBV Stock Slips as AbbVie Faces Opioid Lawsuits | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Investors Business Daily | 2022-07-29 08:57:50 | https://www.investors.com/news/technology/abbvie-stock-abbv-earnings-q2-2022/ | AbbVie narrowly topped second-quarter expectations Friday and reaffirmed its earnings outlook. But AbbVie stock fell early. | AbbVie Ekes Out Narrow Second-Quarter Beat, Confirms 2022 Outlook | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Market Watch | 2022-07-29 08:17:47 | https://www.marketwatch.com/story/abbvie-reports-an-increase-in-second-quarter-revenue-led-by-sales-of-humira-2022-07-29 | Shares of AbbVie Inc. ABBV, -0.93% were down 1.3% in premarket trading on Friday though the company met earnings and revenue expectations for the second quarter of the year. AbbVie had earnings of $924 million, or 51 cents per share, in the second quarter of this year, compared with $766 million, or 42 cents per share,... | AbbVie reports an increase in second-quarter revenue, led by sales of Humira | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarijuanaStocks | 2022-07-28 14:20:10 | https://marijuanastocks.com/best-cannabis-stocks-to-buy-long-term-2-to-watch-before-august/ | Are These Good Long Term Investments Into Cannabis? The post Best Cannabis Stocks To Buy Long Term? 2 To Watch Before August appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™. | Best Cannabis Stocks To Buy Long Term? 2 To Watch Before August | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-07-28 08:41:03 | https://www.marketbeat.com/originals/should-you-buy-abbvie-ahead-of-earnings/?SNAPI | AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment? | Should You Buy AbbVie Ahead Of Earnings? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-27 18:34:14 | https://www.zacks.com/stock/news/1959071/abbvie-q2-preview-can-shares-retain-their-strength | There has been a surplus of buyers for AbbVie shares in 2022, with shares gaining a double-digit 15% and outperforming its Zacks Industry by a fair margin. | AbbVie Q2 Preview: Can Shares Retain Their Strength? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Reuters | 2022-07-27 18:18:00 | https://www.reuters.com/business/healthcare-pharmaceuticals/abbvies-allergan-reaches-2-bln-opioid-lawsuit-settlement-bloomberg-news-2022-07-27/ | AbbVie Inc's unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter. | AbbVie's Allergan reaches $2 billion opioid lawsuit settlement - Bloomberg News | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-25 16:16:18 | https://www.zacks.com/commentary/1957361/3-dividend-kings-suited-perfectly-for-income-investors | Meeting the parameters to join the elite Dividend King group speaks volumes about these companies' well-established and thriving nature. | 3 Dividend Kings Suited Perfectly for Income Investors | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-25 10:03:13 | https://www.zacks.com/stock/news/1956988/here-is-what-to-know-beyond-why-abbvie-inc-abbv-is-a-trending-stock | Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store. | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
PRNewsWire | 2022-07-25 08:00:00 | https://www.prnewswire.com/news-releases/abbvie-and-allergan-aesthetics-to-present-new-data-from-leading-neurotoxin-portfolio-at-toxins-2022-conference-301592023.html | – Data analyses of onabotulinumtoxinA (BOTOX ® ) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and long-term use – Study results on onabotulinumtoxinA (BOTOX® Cos... | AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-07-25 03:11:21 | https://seekingalpha.com/article/4525460-my-top-3-picks-2022-revisited-2-huge-winners-google-stock-falters | It's time to revisit these top picks as we are more than halfway through a tumultuous 2022. AbbVie and VICI have vastly outperformed the market, but Alphabet is struggling. | My Top 3 Picks For 2022 Revisited: 2 Huge Winners, But Google Falters | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-07-24 09:35:33 | https://investorplace.com/value-stocks-trading-at-a-discount/ | These value stocks trading at discount are trading at attractive valuations while their fundamentals continue to impress. The post 7 Value Stocks Trading at a Massive Discount Right Now appeared first on InvestorPlace. | 7 Value Stocks Trading at a Massive Discount Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-07-22 16:58:58 | https://www.gurufocus.com/news/1833469/2ndquarter-earnings-results-could-impact-drug-company-shares | The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-tier drug companies in the second half, including interest rates, federal drug pricing actions and scrutiny by the Federal... | 2nd-Quarter Earnings Results Could Impact Drug Company Shares | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-22 11:44:34 | https://www.zacks.com/stock/news/1956464/abbvie-abbv-reports-next-week-wall-street-expects-earnings-growth | AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-22 11:00:00 | https://www.fool.com/investing/2022/07/22/could-abbvie-stock-help-you-retire-a-millionaire/ | The healthcare company has been outperforming the S&P over the past decade by a wide margin. | Could AbbVie Stock Help You Retire a Millionaire? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-21 13:14:41 | https://www.zacks.com/stock/news/1955879/healthcare-etfs-in-focus-ahead-of-q2-earnings | The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio. | Healthcare ETFs in Focus Ahead of Q2 Earnings | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Stockmarketcom | 2022-07-20 16:10:35 | https://stockmarket.com/featured/3-high-yield-dividend-stocks-to-watch-today-2022-07-20 | Do you have these top high-yield dividend stocks on your watchlist right now? | 3 High Yield Dividend Stocks To Watch Today | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-07-20 06:15:47 | https://investorplace.com/best-income-stocks/ | With inflation putting a beating on household budgets and earnings, the best income stocks to buy may help mitigate the crisis. The post 7 Best Income Stocks to Buy Now appeared first on InvestorPlace. | 7 Best Income Stocks to Buy Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
MarketBeat | 2022-07-20 01:00:53 | https://www.marketbeat.com/originals/a-dose-of-abbvie-stock-can-help-your-bear-market-portfolio/?SNAPI | AbbVie (NYSE: ABBV) is a conventional stock for unconventional times. And that's exactly why it makes sense to add or hold in your bear market portfolio. | A Dose of AbbVie Stock Can Help Your Bear Market Portfolio | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-19 05:13:00 | https://www.fool.com/investing/2022/07/19/3-dividend-growth-stocks-you-can-buy-now/ | Recession or no recession, these well-established businesses are going to keep on growing. | 3 Dividend Growth Stocks You Can Buy Now and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-18 20:06:05 | https://www.zacks.com/stock/news/1953964/johnson-johnson-has-been-posting-negative-surprises-a-look-under-the-hood | JNJ Management expects relatively consistent growth for the rest of the year. | Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-18 12:24:03 | https://www.zacks.com/stock/news/1953819/abbvie-abbv-seeks-eu-nod-for-atogepant-to-prevent-migraine | AbbVie (ABBV) submits a regulatory application to the European Union, seeking approval for atogepant, for preventive treatment of migraine. | AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-07-17 06:50:02 | https://investorplace.com/2022/07/best-stocks-for-2022-after-two-quarters-who-holds-lead/ | After the first two quarters of fiscal year 2022, who holds the top spot in the InvestorPlace Best Stocks for 2022 contest? Let's dive in. | Best Stocks for 2022: After Two Quarters, Who Holds The Lead? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-17 05:58:00 | https://www.fool.com/investing/2022/07/17/3-dividend-growth-stocks-to-buy-in-july/ | These three stocks have a lot in common. | 3 Dividend Growth Stocks to Buy in July | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-16 07:15:00 | https://www.fool.com/investing/2022/07/16/want-to-get-richer-5-best-stocks-to-buy-now-and-ho/ | Health and wealth; it doesn't get much better than that. | Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Seeking Alpha | 2022-07-16 00:37:24 | https://seekingalpha.com/article/4523709-abbvie-breaks-out-again | AbbVie performed well in Q1, but gave back a fair amount of those gains in Q2. AbbVie has been basing for a few weeks and may have just broken out of its multi-month downtrend. | AbbVie Breaks Out Again | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-07-14 19:18:19 | https://investorplace.com/safe-dividend-stocks/ | Rising interest rates and talk of an upcoming recession have investors seeking safety in their portfolios with high dividend-paying stocks. The post 7 Safe Dividends Stocks to Buy in July appeared first on InvestorPlace. | 7 Safe Dividends Stocks to Buy in July | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-14 17:00:05 | https://www.zacks.com/stock/news/1952550/3-recession-proof-stocks-up-10-in-2022-to-buy-right-now | Today, we dive into three stocks that are poised to beat inflation and rise above any possible recession. All three names appear worth buying for the second half of 2022 and might be up for consideration as buy-and-hold stocks. | 3 Recession-Proof Stocks Up 10% in 2022 to Buy Right Now | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-14 08:45:00 | https://www.fool.com/investing/2022/07/14/heres-how-you-can-earn-10-of-your-investment-back/ | There's a huge incentive to buy and hold dividend growth stocks. | Here's How You Can Earn 10% of Your Investment Back in Dividends | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
The Motley Fool | 2022-07-13 05:57:00 | https://www.fool.com/investing/2022/07/13/better-dividend-stock-abbvie-or-johnson-johnson/ | Both of these big drugmakers have strong dividend credentials. | Better Dividend Stock: AbbVie or Johnson & Johnson? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-07-12 17:54:27 | https://www.gurufocus.com/news/1822011/abbvie-vs-pfizer-which-drug-stock-offers-greater-value | With stock markets down right now, shares of some value stocks can be bargains. In a shaky economy, stocks of companies that make products that are necessities can be smart choices for value investors. | AbbVie vs. Pfizer: Which Drug Stock Offers Greater Value? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
InvestorPlace | 2022-07-11 10:59:34 | https://investorplace.com/2022/07/7-overlooked-blue-chip-stocks-to-add-to-your-buy-list/ | With investors seeking viable ideas during this strange time, overlooked blue-chip stocks to buy could offer stable contrarian upside. The post 7 Overlooked Blue-Chip Stocks to Add to Your Buy List appeared first on InvestorPlace. | 7 Overlooked Blue-Chip Stocks to Add to Your Buy List | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Zacks Investment Research | 2022-07-11 10:05:09 | https://www.zacks.com/stock/news/1950350/is-trending-stock-abbvie-inc-abbv-a-buy-now | Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. | Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
24/7 Wall Street | 2022-07-11 07:14:15 | https://247wallst.com/investing/2022/07/11/the-7-highest-yielding-dividend-kings-to-buy-now-and-hold-forever/ | Every time a bullish market commentator says things are fine, you can almost count on the market going into a tailspin. | The 7 Highest-Yielding Dividend Kings to Buy Now and Hold Forever | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
GuruFocus | 2022-07-10 15:12:53 | https://www.gurufocus.com/news/1813836/4-undervalued-names-with-very-high-gf-scores | Investors looking for stocks that could potentially outperform are encouraged to consider the GF Score at the top of each summary page. | 4 Undervalued Names With Very High GF Scores | ABBV | 1422a02c-0b5b-47f4-8011-863bf51d1a96 | News |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.